Amneal Loses Bid For 180-Day Generic Exclusivity On Namenda XR
Executive Summary
US FDA's demand for commercial-scale data for memantine extended-release during ANDA review did not amount to change in 'requirements for approval,' judge rules, upholding agency determination that Amneal forfeited marketing exclusivity for failure to obtained tentative approval within 30 months.
You may also be interested in...
Teva Sues US FDA To Obtain 180-Day Exclusivity For Its Generic Restasis
Complaint challenges agency's revised definition of "first applicant," which does not require notice of Paragraph IV certification to obtain exclusivity.
Teva Sues US FDA To Obtain 180-Day Exclusivity For Its Generic Restasis
Complaint challenges agency's revised definition of "first applicant," which does not require notice of Paragraph IV certification to obtain exclusivity.
Rescinding A Refuse-To-File: A Precedent Of Sorts
US FDA’s decision to rescind refuse-to-file letter for Alkermes’ high-profile depression drug is extremely unusual – but not literally unprecedented. One prior example of rescinding an RTF involves an ANDA.